Modality
Gene Editing
MOA
KRASG12Di
Target
GLP-1R
Pathway
Innate Imm
AsthmaHCC
Development Pipeline
Preclinical
Oct 2019
PreclinicalCurrent
NCT04282309
2,200 pts·HCC
2019-10→TBD·Active
NCT08063836
135 pts·HCC
2024-11→TBD·Active
2,335 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q4
Preclinical
Active
Preclinical
Active
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04282309 | Preclinical | HCC | Active | 2200 | PFS |
| NCT08063836 | Preclinical | HCC | Active | 135 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R |